Treatment for hemophilia: recombinant versus plasma-derived coagulationfactors – controversy and debateforever? An ethical medical challenge?

Liras, AntonioGarcía-Tenchard, Rebecca2023-06-192023-06-192013-101747-4086, 1747-4094 (ESSN)10.1586/17474086.2013.834798https://hdl.handle.net/20.500.14352/34703With the eradication of infection by HIV and hepatitis C virus that were common just a few years ago, the most concerning adverse effect resulting from the use of both recombinant and plasma-derived products is the appearance of antibodies (inhibitors) to perfused exogenous factors.”engTreatment for hemophilia: recombinant versus plasma-derived coagulationfactors – controversy and debateforever? An ethical medical challenge?journal articlehttp://informahealthcare.com/toc/err/6/5http://informahealthcare.com/journal/errrestricted access616.151.5HemophiliaTreatmentPlasmaFarmacología (Medicina)Hematología3205.04 Hematología